Market Overview:
The global linezolid market is expected to grow at a CAGR of XX% during the forecast period from 2018 to 2030. The growth in the market can be attributed to factors such as rising incidence of infections, increasing demand for novel antibiotics, and growing awareness about linezolid. By type, the purity >99% segment is expected to grow at a higher CAGR than other segments during the forecast period. This can be attributed to its high efficacy and safety profile. By application, skin and soft tissue infections are expected to account for the largest share of the global linezolid market in 2018. However, pneumonia infections are projected to grow at a higher CAGR during the forecast period owing to increasing incidence of pneumonia globally.
Product Definition:
Linezolid is a synthetic antibiotic used for the treatment of infections caused by Gram-positive bacteria, including methicillin-resistant Staphylococcus aureus (MRSA).
Purity:98%-99%:
98%-99% Purity is a new drug in the market. It's an oxazolidinone antibiotic developed by Bayer and has been submitted for approval to the U.S FDA and EMA. The drug was first approved in Japan under the name, Zyloric (a trade name of Bayer) during 2001-2002 and later approved by USFDA under its generic name during 2003-2004.
Purity:>99%:
Linezolid is an antibiotic used for the treatment of bacterial infections. It has a broad spectrum of activity against most gram-positive and negative bacteria. Linezolid is commercially available as both, branded and generic formulations. The brand name “Purity” was granted to this antibiotic by the FDA in 2003 on the basis that it meets all requirements under federal regulations for purity, quality, and safety of pharmaceuticals (section 862).
Application Insights:
The skin and soft tissue infections segment dominated the global linezolid market in 2017, accounting for over 45% of the total revenue. Linezolid is used for various skin and soft tissue infections, including impetigo, cellulitis, chickenpox or varicella zoster infection (shingles), staphylococcal infection of the face or ears (abscesses), burns injuries (trauma) and diabetic foot ulcers. The drug has shown efficacy in treating these conditions as it reduces inflammation at a molecular level without causing any damage to healthy cells.
Linezolid demand is expected to be driven by its extensive use for treatment of severe pneumonia caused by multi-drug resistant bacteria such as methicillin-resistant Staphylococcus aureus (MRSA). In addition, increasing awareness about this antibiotic among healthcare professionals coupled with rising incidence rates of hospital-acquired pneumonia across the globe is likely to propel growth over the forecast period.
Regional Analysis:
North America dominated the global linezolid market in 2017. The presence of key players, favorable reimbursement policies, and increasing healthcare expenditure are some of the factors responsible for its large share. Linezolid is commercially available in the U.S., whereas it must be approved by FDA before marketing in other countries; this approval process takes about 6-8 months after application is submitted to FDA for review and acceptance or rejection. Thus, until linezolid is marketed globally it can only be purchased from U.S.-based pharmacies via an international prescription issued by a doctor based outside U.S.
Asia Pacific region is expected to grow at a lucrative rate over the forecast period owing to several unmet clinical needs coupled with rapidly improving healthcare infrastructure & facilities along with rising awareness regarding infectious diseases treatment options especially second-line drugs like linezolid that are less expensive than first-line drugs used for treatment purposes (antibiotics).
Growth Factors:
- Increasing incidence of bacterial infections: Linezolid is an effective antibiotic against a wide range of bacteria, including methicillin-resistant Staphylococcus aureus (MRSA). The increasing incidence of bacterial infections will drive the demand for linezolid.
- Rising popularity of linezolid as an alternative to vancomycin: Vancomycin is the most commonly used antibiotic for treating MRSA infections, but it has several drawbacks such as toxicity and the development of resistance. Linezolid is becoming increasingly popular as an alternative to vancomycin due to its lower toxicity and better efficacy against MRSA strains.
- Growing use in hospitals: Linezolid is primarily used in hospitals for the treatment of serious or life-threatening infections caused by multi-drug resistant bacteria. The growing use of linezolid in hospitals will boost the market growth.
- expanding indications for linezolid: Linezolid has been approved by regulatory authorities for the treatment of various typesof infection, including pneumonia, skin and soft tissue infection, and blood stream infection (sepsis). The expanding indicationsfor linezold will fuel market growth overthe forecast period . 5) Availabilityof generic versions: Several generic versionsoflineozold are availablein different countries worldwideat a fractionofthe costof branded formulations
Scope Of The Report
Report Attributes
Report Details
Report Title
Linezolid Market Research Report
By Type
Purity:98%-99%, Purity:>99%
By Application
Skin and Soft Tissue Infections, Pneumonia Infections, Others
By Companies
Hisun Pharmaceuticals USA, SLN Pharmachem, Jubilant Pharma, Actis Generics, Admiron Life Sciences, Sharon, Tetrahedron, Amoli, Hubei Fullstate Chemical
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
240
Number of Tables & Figures
168
Customization Available
Yes, the report can be customized as per your need.
Global Linezolid Market Report Segments:
The global Linezolid market is segmented on the basis of:
Types
Purity:98%-99%, Purity:>99%
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Skin and Soft Tissue Infections, Pneumonia Infections, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Hisun Pharmaceuticals USA
- SLN Pharmachem
- Jubilant Pharma
- Actis Generics
- Admiron Life Sciences
- Sharon
- Tetrahedron
- Amoli
- Hubei Fullstate Chemical
Highlights of The Linezolid Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Purity:98%-99%
- Purity:>99%
- By Application:
- Skin and Soft Tissue Infections
- Pneumonia Infections
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Linezolid Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Linezolid is an antibiotic medication used to treat a variety of infections, including pneumonia. It works by killing bacteria. Linezolid may also be used to prevent infection after surgery.
Some of the key players operating in the linezolid market are Hisun Pharmaceuticals USA, SLN Pharmachem, Jubilant Pharma, Actis Generics, Admiron Life Sciences, Sharon, Tetrahedron, Amoli, Hubei Fullstate Chemical.
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Linezolid Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Linezolid Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Linezolid Market - Supply Chain
4.5. Global Linezolid Market Forecast
4.5.1. Linezolid Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Linezolid Market Size (000 Units) and Y-o-Y Growth
4.5.3. Linezolid Market Absolute $ Opportunity
5. Global Linezolid Market Analysis and Forecast by Type
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Type
5.2.2. Y-o-Y Growth Projections by Type
5.3. Linezolid Market Size and Volume Forecast by Type
5.3.1. Purity:98%-99%
5.3.2. Purity:>99%
5.4. Absolute $ Opportunity Assessment by Type
5.5. Market Attractiveness/Growth Potential Analysis by Type
6. Global Linezolid Market Analysis and Forecast by Application
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Application
6.2.2. Y-o-Y Growth Projections by Application
6.3. Linezolid Market Size and Volume Forecast by Application
6.3.1. Skin and Soft Tissue Infections
6.3.2. Pneumonia Infections
6.3.3. Others
6.4. Absolute $ Opportunity Assessment by Application
6.5. Market Attractiveness/Growth Potential Analysis by Application
7. Global Linezolid Market Analysis and Forecast by Sales Channel
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Sales Channel
7.2.2. Y-o-Y Growth Projections by Sales Channel
7.3. Linezolid Market Size and Volume Forecast by Sales Channel
7.3.1. Manufacturer/Distributor/Service Provider
7.3.2. Aftermarket
7.4. Absolute $ Opportunity Assessment by Sales Channel
7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel
8. Global Linezolid Market Analysis and Forecast by Region
8.1. Market Trends
8.2. Introduction
8.2.1. Basis Point Share (BPS) Analysis by Region
8.2.2. Y-o-Y Growth Projections by Region
8.3. Linezolid Market Size and Volume Forecast by Region
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa (MEA)
8.4. Absolute $ Opportunity Assessment by Region
8.5. Market Attractiveness/Growth Potential Analysis by Region
8.6. Global Linezolid Demand Share Forecast, 2019-2026
9. North America Linezolid Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.2. North America Linezolid Market Size and Volume Forecast by Country
9.2.1. U.S.
9.2.2. Canada
9.3. Absolute $ Opportunity Assessment by Country
9.4. North America Linezolid Market Size and Volume Forecast by Application
9.4.1. Skin and Soft Tissue Infections
9.4.2. Pneumonia Infections
9.4.3. Others
9.5. Basis Point Share (BPS) Analysis by Application
9.6. Y-o-Y Growth Projections by Application
9.7. North America Linezolid Market Size and Volume Forecast by Type
9.7.1. Purity:98%-99%
9.7.2. Purity:>99%
9.8. Basis Point Share (BPS) Analysis by Type
9.9. Y-o-Y Growth Projections by Type
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.10.4. By Sales Channel
9.11. North America Linezolid Demand Share Forecast, 2019-2026
10. Latin America Linezolid Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Latin America Average Pricing Analysis
10.2. Latin America Linezolid Market Size and Volume Forecast by Country
10.2.1. Brazil
10.2.2. Mexico
10.2.3. Rest of Latin America
10.3. Absolute $ Opportunity Assessment by Country
10.4. Latin America Linezolid Market Size and Volume Forecast by Application
10.4.1. Skin and Soft Tissue Infections
10.4.2. Pneumonia Infections
10.4.3. Others
10.5. Basis Point Share (BPS) Analysis by Application
10.6. Y-o-Y Growth Projections by Application
10.7. Latin America Linezolid Market Size and Volume Forecast by Type
10.7.1. Purity:98%-99%
10.7.2. Purity:>99%
10.8. Basis Point Share (BPS) Analysis by Type
10.9. Y-o-Y Growth Projections by Type
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.10.4. By Sales Channel
10.11. Latin America Linezolid Demand Share Forecast, 2019-2026
11. Europe Linezolid Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Europe Average Pricing Analysis
11.2. Europe Linezolid Market Size and Volume Forecast by Country
11.2.1. Germany
11.2.2. France
11.2.3. Italy
11.2.4. U.K.
11.2.5. Spain
11.2.6. Russia
11.2.7. Rest of Europe
11.3. Absolute $ Opportunity Assessment by Country
11.4. Europe Linezolid Market Size and Volume Forecast by Application
11.4.1. Skin and Soft Tissue Infections
11.4.2. Pneumonia Infections
11.4.3. Others
11.5. Basis Point Share (BPS) Analysis by Application
11.6. Y-o-Y Growth Projections by Application
11.7. Europe Linezolid Market Size and Volume Forecast by Type
11.7.1. Purity:98%-99%
11.7.2. Purity:>99%
11.8. Basis Point Share (BPS) Analysis by Type
11.9. Y-o-Y Growth Projections by Type
11.10. Market Attractiveness/Growth Potential Analysis
11.10.1. By Country
1110.2. By Product Type
11.10.3. By Application
11.10.4. By Sales Channel
11.11. Europe Linezolid Demand Share, 2019-2026
12. Asia Pacific Linezolid Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Asia Pacific Average Pricing Analysis
12.2. Asia Pacific Linezolid Market Size and Volume Forecast by Country
12.2.1. China
12.2.2. Japan
12.2.3. South Korea
12.2.4. India
12.2.5. Australia
12.2.6. Rest of Asia Pacific (APAC)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Asia Pacific Linezolid Market Size and Volume Forecast by Application
12.4.1. Skin and Soft Tissue Infections
12.4.2. Pneumonia Infections
12.4.3. Others
12.5. Basis Point Share (BPS) Analysis by Application
12.6. Y-o-Y Growth Projections by Application
12.7. Asia Pacific Linezolid Market Size and Volume Forecast by Type
12.7.1. Purity:98%-99%
12.7.2. Purity:>99%
12.8. Basis Point Share (BPS) Analysis by Type
12.9. Y-o-Y Growth Projections by Type
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.10.4. By Sales Channel
12.11. Asia Pacific Linezolid Demand Share, 2019-2026
13. Middle East & Africa Linezolid Market Analysis and Forecast
13.1. Introduction
13.1.1. Basis Point Share (BPS) Analysis by Country
13.1.2. Y-o-Y Growth Projections by Country
13.1.3. Asia Pacific Average Pricing Analysis
13.2. Middle East & Africa Linezolid Market Size and Volume Forecast by Country
13.2.1. Saudi Arabia
13.2.2. South Africa
13.2.3. UAE
13.2.4. Rest of Middle East & Africa (MEA)
13.3. Absolute $ Opportunity Assessment by Country
13.4. Middle East & Africa Linezolid Market Size and Volume Forecast by Application
13.4.1. Skin and Soft Tissue Infections
13.4.2. Pneumonia Infections
13.4.3. Others
13.5. Basis Point Share (BPS) Analysis by Application
13.6. Y-o-Y Growth Projections by Application
13.7. Middle East & Africa Linezolid Market Size and Volume Forecast by Type
13.7.1. Purity:98%-99%
13.7.2. Purity:>99%
13.8. Basis Point Share (BPS) Analysis by Type
13.9. Y-o-Y Growth Projections by Type
13.10. Market Attractiveness/Growth Potential Analysis
13.10.1. By Country
13.10.2. By Product Type
13.10.3. By Application
13.10.4. By Sales Channel
13.11. Middle East & Africa Linezolid Demand Share, 2019-2026
14. Competition Landscape
14.1. Global Linezolid Market: Market Share Analysis
14.2. Linezolid Distributors and Customers
14.3. Linezolid Market: Competitive Dashboard
14.4. Company Profiles (Details Overview, Financials, Developments, Strategy)
14.4.1. Hisun Pharmaceuticals USA
14.4.1.1. Overview
14.4.1.2. Financials
14.4.1.3. Developments
14.4.1.4. Strategic Outlook
14.4.2. SLN Pharmachem
14.4.2.1. Overview
14.4.2.2. Financials
14.4.2.3. Developments
14.4.2.4. Strategic Outlook
14.4.3. Jubilant Pharma
14.4.3.1. Overview
14.4.3.2. Financials
14.4.3.3. Developments
14.4.3.4. Strategic Outlook
14.4.4. Actis Generics
14.4.4.1. Overview
14.4.4.2. Financials
14.4.4.3. Developments
14.4.4.4. Strategic Outlook
14.4.5. Admiron Life Sciences
14.4.5.1. Overview
14.4.5.2. Financials
14.4.5.3. Developments
14.4.5.4. Strategic Outlook
14.4.6. Sharon
14.4.6.1. Overview
14.4.6.2. Financials
14.4.6.3. Developments
14.4.6.4. Strategic Outlook
14.4.7. Tetrahedron
14.4.7.1. Overview
14.4.7.2. Financials
14.4.7.3. Developments
14.4.7.4. Strategic Outlook
14.4.8. Amoli
14.4.8.1. Overview
14.4.8.2. Financials
14.4.8.3. Developments
14.4.8.4. Strategic Outlook
14.4.9. Hubei Fullstate Chemical
14.4.9.1. Overview
14.4.9.2. Financials
14.4.9.3. Developments
14.4.9.4. Strategic Outlook
14.4.10. COMPANY 10
14.4.10.1. Overview
14.4.10.2. Financials
14.4.10.3. Developments
14.4.10.4. Strategic Outlook
14.4.11. COMPANY 11
14.4.11.1. Overview
14.4.11.2. Financials
14.4.11.3. Developments
14.4.11.4. Strategic Outlook
14.4.12. COMPANY 12
14.4.12.1. Overview
14.4.12.2. Financials
14.4.12.3. Developments
14.4.12.4. Strategic Outlook
14.4.13. COMPANY 13
14.4.13.1. Overview
14.4.13.2. Financials
14.4.13.3. Developments
14.4.13.4. Strategic Outlook
14.4.14. COMPANY 14
14.4.14.1. Overview
14.4.14.2. Financials
14.4.14.3. Developments
14.4.14.4. Strategic Outlook
14.4.15. COMPANY 15
14.4.15.1. Overview
14.4.15.2. Financials
14.4.15.3. Developments
14.4.15.4. Strategic Outlook
14.4.16. COMPANY 16
14.4.16.1. Overview
14.4.16.2. Financials
14.4.16.3. Developments
14.4.16.4. Strategic Outlook
14.4.17. COMPANY 17
14.4.17.1. Overview
14.4.17.2. Financials
14.4.17.3. Developments
14.4.17.4. Strategic Outlook
14.4.18. COMPANY 18
14.4.18.1. Overview
14.4.18.2. Financials
14.4.18.3. Developments
14.4.18.4. Strategic Outlook
14.4.19. COMPANY 19
14.4.19.1. Overview
14.4.19.2. Financials
14.4.19.3. Developments
14.4.19.4. Strategic Outlook
14.4.20. COMPANY 20
14.4.20.1. Overview
14.4.20.2. Financials
14.4.20.3. Developments
14.4.20.4. Strategic Outlook
